Journal Mobile Options
Table of Contents
Vol. 77, No. 3-4, 1997
Issue release date: 1997
Cytogenet Cell Genet 1997;77:290–295
Gene Mapping, Cloning, and Sequencing

Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours

Matas N. · Thygesen P. · Stacey M. · Risch A. · Sim E.
Department of Pharmacology, University of Oxford, Oxford (UK)


Arylamine N-acetyltransferases (NATs) are encoded at two loci on 8p22, a region subject to deletions in bladder tumours. The two functional genes (AAC1 and AAC2 alias NAT1 and NAT2) without introns in the coding region, encode enzymes which metabolise carcinogens, including bladder carcinogens. They are both multi-allelic and certain alleles have been implicated as susceptibility factors in bladder cancer. There is a third N-acetyltransferase gene, a pseudogene, AACP alias NATP, which we show is also located on chromosome 8 at the p22 region. We have mapped a series of YAC clones (ICI and CEPH) containing the NAT genes and the markers D8S21 an RFLP marker, and D8S261, a microsatellite marker. We show that D8S21 is a portion of the coding region of AAC2. The order of genes in this region, covering some 2 Mb, is TEL–D8S261–AAC1–AACP–AAC2 (D8S21) –CEN. The restriction map also illustrates that there are likely to be other expressed genes in the region through the identification of CpG islands.

 goto top of outline Author Contacts

Request reprints from Prof. E. Sim, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT (UK); fax: 44-1865-271853; e-mail

 goto top of outline Article Information

Received 7 January 1997
Published online: May 20, 2008
Number of Print Pages : 6

 goto top of outline Publication Details

Cytogenetic and Genome Research

Vol. 77, No. 3-4, Year 1997 (Cover Date: 1997)

Journal Editor: Schmid M. (Würzburg)
ISSN: 1424–8581 (Print), eISSN: 1424–859X (Online)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.